Reports

Stephan Emmerth

Stephan Emmerth

PhD | Director Therapeutic Innovation and BaseLaunch


Tel. +41 61 295 50 17

stephan.notexisting@nodomain.comemmerth@baselarea.notexisting@nodomain.comswiss
report Life Sciences
(img: Arjona Ferreira/Myovant Sciences)

(img: Arjona Ferreira/Myovant Sciences)

20.07.2017

Myovant strengthens executive team

The pharmaceutical company Myovant Sciences has bolstered its management with four new hires. Among them is a new chief medical officer. The company is also increasing its regulatory competences.

Juan Camilo Arjona Ferreira is the new chief medical officer at Myovant, announced the company in a statement. As vice-president of the Japanese pharma company Shionogi, he was responsible for the clinical development programme in the USA. Before that, he headed clinical development in women’s health products at Merck.

Also strengthening Myovant’s executive team is Teresa Perney, who joins as vice-president of regulatory affairs and quality assurance. She brings with her experience at pharmaceutical firms including Pfizer, Roche and Genentech.

Myovant is a subsidiary of Roivant Sciences, which announced at the end of 2016 that it was relocating its headquarters to Basel. BaselArea.swiss supported the company in choosing its location.

Myovant’s lead compound is Relugolix, which recently produced positive results in clinical trials on the uterine disorder endometriosis. The compound is also to enter a phase 3 clinical trial on the treatment of prostate cancer.

Completing the new executive hires are Matthew Lang and Andria Langenberg. The former vice-president of Gilead Sciences, Lang was responsible for different areas in the litigation department. At Myovant, he will be general counsel and corporate secretary. Langenberg has decades of experience in drug development, most recently at Medivation. She joins Myovant as head of drug safety and pharmacovigilance.

Myovant president and CEO, Lynn Seely, highlighted the proven leadership qualities of the new employees, explaining that they would support the company’s development of innovative drugs for women’s health and endocrine diseases.   

Cookies

BaselArea.swiss uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.

Ok